If you are a member of the media and have questions about Bayer in Canada, please contact Marija Mandic, Director of Communications, at email@example.com, or 416-240-5376, or Emily Hanft, Senior Business Communications Partner, at firstname.lastname@example.org, or 416-240-5466.
May 7, 2013Saluting Canadian innovators who embody Bayer’s philosophy: Science for a Better Life
May 6, 2013Many Canadian pet owners put animal’s health before their own
April 22, 2013Bayer Proves it is Easy Being Green
April 19, 2013Bayer’s Xarelto® (rivaroxaban tablet) Now Approved for the Treatment of Venous Thromboembolic Events and Prevention of Recurrent
April 2, 2013Bayer celebrates 150 years of Science for a Better Life
March 25, 2013First New Colon Cancer Treatment Since 2006 Received Priority Review From Health Canada And Is Now Approved For Canadian...
December 10, 2012Bayer Bee Care Center Helps Solve Bee Health’s Toughest Challenges
November 26, 2012Bayer Expands Leadership in Medical Information Technology through Acquisition of Toronto-based Radimetrics, Inc.
November 13, 2012New Canadian-Led Global Study of Xarelto® (rivaroxaban tablet) Initiated in Patients with Coronary or Peripheral Artery Disease
October 17, 2012Canadians in eight provinces now eligible for newly reimbursed treatment for stroke prevention in atrial fibrillation
October 15, 2012Bayer’s Stivarga® (regorafenib) Tablets Approved by the U.S. FDA for the Treatment of Metastatic Colorectal Cancer
October 10, 2012Bayer celebrates six years at the top!
April 23, 2012Once-daily oral anticoagulant receives positive Common Drug Review recommendation for stroke prevention in atrial fibrillation
April 23, 2012Bayer Inc. Celebrates Four Years as One of Canada’s 55 Greenest Employers
April 18, 2012BAYER INC. WELCOMES NEW PRESIDENT & CEO TO CANADA!
April 17, 2012Bayer HealthCare Launches Advertising Campaign for Pet Owners
February 21, 2012Xarelto® Approved for the Treatment of Deep Vein Thrombosis without Symptomatic Pulmonary Embolism
January 17, 2012Xarelto® Approved for Stroke Prevention in Atrial Fibrillation
December 1, 2011Bayer Inc. Medical Statement: Safety of Hormonal Combined Oral Contraceptives (YAZ®, Yasmin®)
November 29, 2011Visanne® is the first oral treatment approved in more than 10 years for Canadian women with endometriosis